Find out more about how we meet the challenges of research, development and manufacturing data management.
We dig deep into some of the compelling reasons to move from on-premise to a cloud-based laboratory data management system.
Discover why CMC continuity is the missing link between development and manufacturing, and how preserving connected product and process knowledge helps reduce handoff risk, accelerate tech transfer, and strengthen manufacturing readiness.
As bioanalytical studies grow more complex, transparency is emerging as a strategic advantage. Explore how CROs and sponsors working from a single source of truth can accelerate development without compromising quality or compliance.
A succinct, practical guide for CDMOs that are navigating digital maturity, cost management, and competitive differentiation
Bioanalytical studies generate more than results. They create a chain of scientific and operational context that must remain connected from study design and method execution through review, reporting and reuse. Explore how bioanalytical context management helps CROs and sponsors improve traceability, accelerate study delivery and build trusted, AI-ready evidence.
Too much scientific data lives in disconnected systems, free text or spreadsheets. Without capturing structure and context at the bench, it is hard to reuse data for analytics, automation and AI at scale. Discover how to move from fragmented records to reusable scientific insight.
AI is generating powerful hypotheses in biopharma but many of these insights stall at the bench. In this blog, Anirban Mudi introduces the concept of the governed middle – the operational layer that connects dry lab AI to governed wet lab execution.
IDBS and Alchemi have partnered to connect Alchemi’s AI agents to governed data in IDBS Polar, enabling biopharma teams to produce CMC reports and submission dossiers faster—with 21 CFR Part 11 compliance and human review maintained throughout.
Labs don’t lose productivity because science fails—they lose it because systems don’t connect. Explore five common lab operations challenges and how connected data improves efficiency, compliance and time to insight.
IDBS’ flagship i3 2026 customer forum in Boston brought together BioPharma leaders to show how organizations are moving from vision to reality—translating complex workflows, legacy processes and regulatory constraints into systems that work at scale.
Learn how cloud migration helps BioPharma organizations respond faster to change by reducing costs, improving resilience, and accelerating innovation.
How should BioPharma companies distinguish between moonshot automation and validated digital tools? Marc Smith shares his perspective in a Pharma’s Almanac roundtable, explaining why AI derives its value from validated ELNs, LIMS and regulated data platforms—it does not replace them.
IDBS announces i3 2026, its flagship customer and partner forum in Boston. The one-day event brings BioPharma leaders together to tackle the hardest scientific data challenges ahead of Bio-IT World.
Cloud migration boosts innovation in BioPharma, but only if validation keeps pace. Discover the essentials for a compliant, secure move.
IDBS has been awarded the Best Biologics Digitalisation: Software Innovation Award at the 2026 Asia Pacific Biopharma Excellence Awards, recognizing the company’s significant contributions to advancing digital transformation across the biopharma industry. Presented during the Biologics World Asia conference in Singapore, this honor highlights IDBS’ commitment to enhancing process efficiency, data quality, and scientific innovation through its industry-leading cloud software solutions.
Stability studies often slip when timepoints are managed across spreadsheets, emails, and disconnected tools. This article explains the root causes of drift and how stability teams can regain control with clearer visibility, readiness, and governed scheduling.
GxP compliance is critical, but navigating complex regulations can feel overwhelming. This blog explores practical strategies—like risk-based validation, automation and audit-ready processes—that help organizations stay compliant while accelerating operations
As 2025 draws to a close, IDBS celebrates customer successes and key innovations that advanced scientific digital transformation – from launching Polar Control and accelerating tech transfer to expanding domain-specific workflow accelerators – all aimed at reducing time to ROI and enabling faster, smarter decisions.
Vantive has partnered with IDBS to deploy the Polar cloud platform across global sites, advancing digital transformation in vital organ therapy. This collaboration streamlines data management, enhances collaboration, and accelerates innovation to deliver life-saving therapies worldwide.
i3 – Innovation, Ideas, Insight – is an exclusive customer and partner event designed to foster collaboration and spark innovation across the BioPharma sector. This year’s gathering brought together industry leaders, technical experts and IDBS’ customers to explore the future of scientific data management, artificial intelligence (AI) and digital transformation.
Reflecting on two inspiring days at our Woking office, i3 2025 brought together a community of over 40 BioPharma professionals from across the globe to explore the future of lab data management, artificial intelligence (AI) and digital transformation.
Discover how a lab informatics platform can streamline drug development by improving PK studies, reducing IND risk, and accelerating ROI.
IDBS shares results from its latest survey into the current challenges and future priorities for lab data management in the BioPharma industry.
With the critical role of high-quality data, today’s bioanalytical labs must rethink their approach to data management, and center it on connected data.
We know that identification of true reductions in environmental impact through process modeling and Life Cycle Assessment can only be made with access to quality data.
IDBS shares results from its latest survey into the current challenges and future priorities for lab data management in the BioPharma industry.
Lab informatics systems are rapidly becoming indispensable necessities. But are current solutions meeting both present and future needs?
By leveraging advanced DMPK software solutions, you can streamline your workflows and make informed decisions with confidence.
The i3 2025 call for speakers is now open! i3 is our annual customer and user group meeting, representing innovation, ideas and insight.
Accelerate drug development with AI. Enhance process intelligence and achieve gold-standard data sets with the right digital tools and improved maturity.
IDBS has been awarded the Best Bioprocessing Supplier Award: Software, at the Asia Pacific Biopharma Excellence Awards (ABEA) 2025.
BioIVT has implemented the IDBS E-WorkBook platform, significantly reducing study cycle times by at least 30%.
IDBS is excited to announce the launch of Polar Control, a groundbreaking module designed to transform process management.
Despite advancements in laboratory informatics tools, without accurate documentation of parameters and processes, drug development teams face challenges like data silos, data integrity issues and delayed insights.
Could digital transformation hold the key to streamlining tech transfers, optimizing process control and reducing costly delays?
Many scientists spend time making data useable. Prioritize clean data — whether you store it on paper, in the cloud or in ancient scrolls.
IDBS, announced today that it has achieved a Bronze Medal from EcoVadis, a global leader in business sustainability assessments.
Why the BioPharma industry needs to shift its focus to capturing, managing and leveraging parameter and process data to create process knowledge.
Green practices have become everyone’s responsibility. Now, companies have intensified practices in BioPharma, whose operations have big environmental impacts.
Explore strategies for maximizing ROI in pharma through advanced analytics, streamlined operations and an interconnected data management platform.
Life science companies could be leaving $180 billion on the table from failing to fully adopt digital solutions.
IDBS is pleased to announce the completion of its latest SOC 2 assessment, which now includes Processing Integrity.
In a world of digital transformation, achieving business agility and data security remains a challenge despite advancements in cloud tech.
Our experts deliver the practical steps organizations should take to reap the value of AI in digital transformation.
Discover our 5-step guide to digital maturity, covering initial digitization to innovation, strategic use of data, executive buy-in, and a data strategy.
Relying on fragmented data becomes problematic when teams need to dissect cell line performance data and that data is not in a digital backbone.
IDBS is thrilled to announce that it has been awarded the Best Biologics Digitalization Award at Asia Pacific Biologics CMO Excellence Awards 2024.
We’re delighted to announce that IDBS is recognized as the top life sciences informatics company in Europe 2024 by Life Sciences Review.
IDBS announces that its ISO 9001 & 27001 certifications have completed their major reassessment cycle and are valid for a further 3 years.
Why do many BioPharma organizations still struggle to gain the crucial benefits they desire from their data and digital transformation tools?
Discover the significance of digital transformation and its impact on various aspects of organizational operations.
In BioPharma manufacturing, data integrity is key, but challenging. Contextualization and transparency ensure data exchange, enabling early risk detection.
Poor data capture can result in rework, repetition and delayed submission. Improve data management via data standards and structured data.
Data integrity practices in biopharma are evolving. How can you ensure that the data used for AI and ML analysis is of high quality?
We dig deep into some of the compelling reasons to move from on-premise to a cloud-based laboratory data management system.
Discover the pivotal role of cloud computing in facilitating generative AI, optimizing data management and enhancing scalability.
Leaders in BioPharma digital transformation share success stories from domestic and international clients at a well-attended event.
An intelligent and data-driven digital transformation is the key to data intelligence. Discover how in 5 simple steps.
Discover why pharmaceutical companies must focus on bridging internal digital literacy gaps as they invest in AL and ML tools.
Using cloud-based data sharing platforms can enable better collaboration among pharmaceutical manufacturing partners with differing digital maturity levels.
Explore the value of negative results and how proper data management enables your digital maturity journey towards scientific advancement.
IDBS announces the hire of an experienced business leader to expand and support customers for IDBS Polar and PIMS in South Korea.
For data to be useful for AI, it must be well contextualized and easily accessible across systems and processes.
Moving from spreadsheets to automated data collection could be revolutionary. It’s time for the biopharma industry to embrace end-to-end digitalization.
ELNs are still relevant to the pharma lab but must form part of a more comprehensive data strategy and ecosystem or they can impede progress.
Labs generate more data than ever, but turning data into intelligence is another story. Lab leaders want to make data actionable.
Unlocking the potential of AI and ML, digital twins and other advanced analytics for accelerated drug discovery requires good data on which to build upon.
IDBS has partnered with PharmaEssentia on its Polar platform to digitize data management and facilitate collaboration between teams.
Whether labs are in sponsor companies or CROs, the challenge is the same: How do we test more samples in less time, without sacrificing accuracy and quality?
PIMS can help you fully leverage your MES (manufacturing execution system) data for process lifecycle insights and better business decisions.
With so much at stake, you need proper data management and AI/machine learning practices to make a world of difference in early pharma drug research and development.
Discover how PIMS can work synergistically with your existing Electronic Batch Record (EBR) software and why PIMS is a great alternative.
New process definition capabilities in PIMS 5.1, further enhance quality assurance and “right-first-time” initiatives for pharma manufacturers.
Requirements to maintain a GxP environment means researchers must conduct software validation on any updated software so it continues to meet users’ needs.
IDBS is recognized as one of the Top Laboratory Automation Solutions Providers by Pharma Tech Outlook.
Discover how a digital backbone is vital to get transformational insights from your BioPharma development data.
In today’s digital gold rush, data integrity is priceless. Discover how searchable and reusable data can improve efficiency, accelerating drug discovery.
Technology transfer is a necessary evil that exists between drug development and manufacturing. But information sharing is disjointed.
Robust digital workflows in pharma lifecycle management can reduce errors and time to compile data, speeding up regulatory filing.
Thinking of upgrading from a standard ELN? Discover the benefits of centralized BioPharma Lifecycle Management platforms compared to standard ELNs.
Digital initiatives in BPLM provide an opportunity to modernize legacy processes and replace labor-intensive and time-consuming manual methods.
Learn how advances in digital technology and the tailwinds of external forces offer the pharma industry a chance to break out of this paradox.
To bring new therapies to the patients faster, we need to bring people, processes and data together across the full pharma process development lifecycle.
Making data a core deliverable means the right people need to collect information and connect disparate data points through a well-structured data backbone.
Explore why digital maturity is key to transparency and collaboration and enabling accurate forecasting throughout the BioPharmaceutical lifecycle.
The BioPharma industry is facing a multitude of challenging external trends, from the growth in personalized medicine to supply chain disruptions and more.
IDBS associates had the opportunity to attend some events in Q1 and attendees were eager to see, hear and learn more about what’s happening in the industry.
Explore the benefits of GxP computer systems to improve time-to-value so that companies can speed up the development and manufacture of life-saving drugs.
IDBS reveals new process definition-handling capabilities in PIMS 5.0, which enhance quality assurance and validation for pharma manufacturers.
A digital data backbone is key to a successful instrument data integration, speeding processes so that companies can get their therapies to market faster.
IDBS has appointed Pietro Forgione as its new General Manager.
Digital workflows with an “audit-by-exception” approach help reduce errors and time to compile data, and therefore delays to market.
Accelerating tech transfer is vital with new precision medicine and increasing regulatory scrutiny of product quality and management of external partners.
IDBS and SciBite announce a new partnership to shift the way research data platforms approach FAIR (Findable, Accessible, Interoperable, and Reusable) data.
IDBS announces the launch of new data science capabilities for its Polar platform to accelerate BioPharma process optimization.
Data silos and inconsistent data formats increase the chance of errors, which can have a significant impact on business operations. Digital workflows are the answer.
Explore how cloud-based solutions can improve data visibility and transparency so that partners can enjoy equal access to data at all stages of the BioPharma lifecycle.
Discover how a shared data backbone in tech transfer can remove inefficiencies and inconsistencies found in a one-time transfer approach.
Do you have a vision for clean, contextualized data? Is IT accountable to the bench in your lab? Are you willing to value even the most unassuming insights?
Maintaining the balance between compliance and efficiency is what will set a CRO apart in the highly competitive outsourcing landscape and inspire the sponsor’s confidence.
Drug sponsors value – and rely on – the work that CROs perform. CROs have a chance to up their data management game. How can they ensure data quality?
Learn the importance of enterprise control in getting CGTs to market – and the critical systems that enable this control in cell-based therapy manufacturing.
From ensuring data integrity to consolidating IP ownership, effective data management is key for BioPharma companies seeking a competitive edge.
A cloud-only approach provides many benefits, including streamlined validation, automated backups and upgrades, faster deployments and flexibility.
A digital data backbone can improve efficiency in the research process leading to earlier discoveries and lower costs. Discover how now.
Successful tech transfer can be a challenge, even for well-established biotechs. Here’s how to avoid common pitfalls at every stage.
Modernized data governance ensures a solid foundation of data integrity and compliance and achieves an integrated approach to the BioPharma data lifecycle.
Now that we know what a microservice is and why it’s important, let’s explore deploying and managing cloud microservices in GxP environments.
Speeding up time to insight throughout the BioPharma lifecycle requires all data sources to be connected and utilized to form a robust data backbone.
What is a microservice? Let’s explore the term’s meaning, the benefits and how it can help boost your data security.
Life science companies rely on data integrity, security and transparency to ensure success. How do we protect data while keeping it accessible?
BioProcess International took place in Vienna this year, with talks centred around six main streams including cell line development and engineering, cell culture, recovery and purification, viral safety, cell and gene therapy as well as smaller sessions for manufacturing strategy and Industry 4.0 and vaccine manufacturing.
IDBS, a global life sciences software company and the leading innovator in BioPharma Lifecycle Management (BPLM), is excited to bring together over 200 customers, partners and industry experts, including leading CxO and BioPharma companies, at their annual i3 user conference.
In the quest to develop the science and raise funding, developing a digital strategy in general is an afterthought for fledgling biotech companies – if it’s considered at all. Not paying attention to it early, however, can hamper their ability to advance their science and constrain their revenue-generation options.
Modern BioPharma development requires more than just a LIMS and spreadsheets. Learn why in this article by Alberto Pascual, IDBS, featuring Accenture and published in Lab Manager.
IDBS announces the latest release of its Skyland PIMS software, which seamlessly combines product, process, and patient data across the BioPharma life cycle and supply chain, providing insights that accelerate process understanding and ensure product quality.
It’s been a busy year so far. And we’re only at the start of April! Find out what we’ve been up to in this blog.
Compared to most other industries, life science and biopharmaceutical companies have been slow to embrace digital technologies. Why?
As the biopharmaceutical industry begins to embrace advanced data collection and analysis tools, it finds itself facing a challenging question: How can drug manufacturers best harness all that data to improve capacity, reduce bottlenecks and cut costs?
The pandemic exposed the innovation divide between the digitally transformed and those that lagged. Strict regulation made life sciences and BioPharma organizations hesitant to modernize too quickly away from proven legacy methods and technologies, resulting in varying levels of digital transformation. But are they missing out?
Wondering if an ELN can be used as a LIMS? Hear from IDBS and other experts in this interesting piece published in Lab Manager.
Global life sciences software company, IDBS, is excited to publicly announce the location of our new Surrey HQ office address in Woking.
Throughout the past few years, there’s been a clear trend in the makeup of approvals, with biologics representing a growing percentage. But even within biologics, newer technologies like mRNA, cell, and gene therapies are gaining ground. The approvals are not one-off events, but evidence of an exciting long-term trend. Learn more from Christian Marcazzo, General Manager at IDBS, in his article published in Drug Development & Discovery.
A top ten CRO (Contract Research Organization) has chosen IDBS’ Polar™ BioPharma Lifecycle Management to achieve its goal of faster biopharma development.
Around this time last year, the first COVID-19 vaccines were authorized for emergency use. A year before that, COVID-19 had not yet been declared a pandemic. It goes to show how much can change in this industry, as well as how important this sector is. Hear predictions from experts, including Alberto Pascual, in this article, published in Drug Discovery World.
For those of us who develop software that supports the biopharmaceutical/life science industry, the challenges and opportunities in digital transformation are painfully obvious and it can be easy to forget that not everyone sees it that way. Let’s try another way…
While 2021 was another challenging year in many respects, the life science industry still managed some notable achievements.
IDBS, a global life sciences software company and Synthace, a pioneer software for automated biology experimentation and insight sharing, have entered a strategic partnership to provide IDBS Polar users with state-of-the-art data foundations for experimentation in high-throughput process development (HTPD).
IDBS, a Danaher (NYSE:DHR) operating company, announced Polar Insight, bringing new advanced data analytics and visualization tools to the Polar BioPharma Lifecycle Management (BPLM) platform. Extracting valuable insights from process and quality data across the biopharmaceutical lifecycle is a time consuming and error prone process, requiring laborious manual work and multiple steps.
Global life sciences software company IDBS announces the acquisition of biopharmaceutical manufacturing data management and analytics software developer Skyland Analytics, in a move that will create the first BioPharma Lifecycle Management (BPLM) offering that supports therapies from early development through commercial manufacturing.
Global life sciences software company IDBS announces the acquisition of biopharmaceutical manufacturing data management and analytics software developer Skyland Analytics, in a move that will create the first BioPharma Lifecycle Management (BPLM) offering that supports therapies from early development through commercial manufacturing. Skyland Analytics is best known for its Skyland PIMS™ software which seamlessly combines product, process, and patient data across the biopharma lifecycle and supply chain, providing insights that accelerate process understanding and ensure product quality.
When you factor in the unpredictability and complexity of therapies like biologics, the time impacts of poorly managed data are on the order of 6–18 months. Find out more on why legacy data management systems can’t support the directions…
IDBS, the leading innovator in BioPharma Lifecycle Management (BPLM), announces its membership of BioPhorum. BioPhorum offers a space where biopharmaceutical manufacturers and suppliers can come together and discuss the many challenges in the industry, working collaboratively to address them. IDBS has joined the Information Technology Phorum (BPIT) which specifically addresses IT business goals.
The biopharma industry may have been slow to embrace digital technologies, but it’s catching up fast. The innovation we’re seeing in predictive modeling and machine learning could truly revolutionize the entire lifecycle of drug discovery and development. Take a…
India Digital R&D Lab Summit” is our premier annual event where we bring together science, IT and R&D business leaders to share ideas, create new insights and advance innovation!
Life sciences companies are using digital twins for everything from drug discovery to manufacturing. Hear from a panel of experts at MedCity News’ INVEST Digital Health conference, moderated by Accenture, where companies, including IDBS, discuss how this capacity to…
This session will provide an overview of IDBS’s upcoming plans to embed the DLX platform within E-WorkBook Cloud to provide a scalable, enterprise-grade integration backbone for lab connectivity and workflow orchestration. Following the overview, there will be an open forum to discuss some of the challenges in delivering lab integration at scale and feedback on workflows / instrument classes that should be considered for initial prioritization.
IDBS is excited for its upcoming analytics launch and will update attendees to the progress made in this space which will have real benefits to its system administrators and spreadsheet data consumers. E-WorkBook Cloud and Polar customers will learn about new capabilities soon available to them – and E-WorkBook on-premise customers will learn about some business benefits of migrating to the cloud.
Join IDBS’ Alberto Pascual for this roundtable discussion, The Role of Digital Twins in Life Sciences, at the MedCity INVEST Digital Health virtual conference.
In the biopharmaceutical industry, there’s no shortage of data—the issue organizations more often face is how to capture data in ways that derive insight from it. As more and more companies are now recognizing, a fundamentally different approach is…
IDBS, a leading R&D technology and solutions provider and Tableau, the world’s leading analytics platform, announced a strategic partnership to integrate Tableau into the IDBS suite of products. The collaboration will be based on embedding Tableau’s visual and analytics capabilities into the IDBS product offerings.
Roundtable Discussion | IDBS Hosts the Best Practices in Bioanalysis Lab Informatics. Hear how industry experts like Nexelis, AbbVie, and ICON plc are tackling digital lab challenges
Danaher Chief Science Officer Jose-Carlos Gutierrez-Ramos explores how the biopharma rule book has been rewritten by the pandemic and what to expect from the future of genomic medicines in this exclusive new article for Pharmaceutical Executive magazine…
Alberto Pascual, IDBS, tells MedCity News how digital twins can help advance innovation in R&D…
There was a flurry of activity on social media in June when John Erickson et al. published in Biotechnology and Bioengineering on end-to-end collaboration to transform development and manufacturing of biopharmaceuticals.
i3 is our premier annual customer event where we bring together science, IT and R&D business leaders to share ideas, create new insights and advance innovation!
Efficient data management is critical to meet the demand for fast drug development – especially today…
In this webinar IDBS will share how an innovative approach to biopharma lifecycle management supports true QbD and can accelerate development to bring products to market faster.
One of the lasting legacies of the COVID-19 pandemic is heightened awareness of manufacturing challenges and supply chain vulnerabilities in the biopharma industry and the impact this can have on public health. Issues have occurred at every stage of the supply chain, from the availability of raw materials to quality concerns with active pharmaceutical ingredients (APIs), and finished dosage forms and restrictive cold chain requirements.
Join Alberto Pascual, IDBS’s Director of Data Science and Analytics where he will discussing how you can join the digital transformation revolution by democratizing the use of advance analytics!
